Implementing HIV pre-exposure prophylaxis (PrEP): let's not get caught with our pants down

Show simple item record Saxton, Peter en Giola, M en Coughlan, E en Rich, J en Azariah, S en Ludlam, A en O'Toole, C en Pohl, M en Myers, J en 2019-03-21T01:40:05Z en 2018-08-31 en
dc.identifier.citation New Zealand Medical Journal 131(1481):64-73 31 Aug 2018 en
dc.identifier.issn 0028-8446 en
dc.identifier.uri en
dc.description.abstract HIV pre-exposure prophylaxis (PrEP) is a daily pill that prevents HIV acquisition. In March 2018, New Zealand became one of the first countries in the world to publicly fund PrEP for individuals at high risk. PrEP promises significantly improved HIV control but is unfamiliar to most health practitioners here, compromising its potential. In this article we review the rationale for PrEP and identify barriers to rapid implementation. The latter include: consumer and health practitioner awareness; acceptability; scale-up targets; prescribing and pharmacy bottlenecks; service capacity to manage follow-up; primary care training; monitoring systems for uptake and quality; equity; eligibility; risk compensation and policy. Many of these areas are ripe for research and innovation. By addressing these obstacles we can realise the potential of PrEP and move closer to ending HIV in Aotearoa/New Zealand. en
dc.format.medium Electronic en
dc.language eng en
dc.publisher New Zealand Medical Association en
dc.relation.ispartofseries New Zealand Medical Journal en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri en
dc.rights.uri en
dc.subject Humans en
dc.subject HIV Infections en
dc.subject Amphetamine-Related Disorders en
dc.subject Drug Combinations en
dc.subject Anti-HIV Agents en
dc.subject Treatment Outcome en
dc.subject Risk Factors en
dc.subject Morals en
dc.subject Unsafe Sex en
dc.subject Patient Selection en
dc.subject Sexual Partners en
dc.subject Vulnerable Populations en
dc.subject Cost-Benefit Analysis en
dc.subject Female en
dc.subject Male en
dc.subject Healthcare Disparities en
dc.subject Pre-Exposure Prophylaxis en
dc.subject Tenofovir en
dc.subject Emtricitabine en
dc.subject Transgender Persons en
dc.subject Sexual and Gender Minorities en
dc.title Implementing HIV pre-exposure prophylaxis (PrEP): let's not get caught with our pants down en
dc.type Journal Article en
pubs.issue 1481 en
pubs.begin-page 64 en
pubs.volume 131 en
dc.rights.holder Copyright: NZMA en en
pubs.end-page 73 en
pubs.publication-status Published en
dc.rights.accessrights en
pubs.subtype Article en
pubs.elements-id 754940 en Medical and Health Sciences en Population Health en Social & Community Health en
dc.identifier.eissn 1175-8716 en
pubs.record-created-at-source-date 2019-08-15 en
pubs.dimensions-id 30161114 en

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace